6/28/23, 9:54 PM EMPA-KIDNEY Pathway Feedback Search Clinical Topics Home Studies EMPA KIDNEY EMPA KIDNEY Disease Chronic kidney disease Trial question What is the role of empagliflozin in patients with CKD? Study design Multi-center Double blinded RCT Population Characteristics of study participants 33.0% female N = 6609 67.0% male 6609 patients (2192 female, 4417 male) Inclusion criteria: patients with CKD with an eGFR 20 and < 45 mL/min/1.73 m , or 45 and < 90 mL/min/1.73 m with a urinary albumin-to-creatinine ratio 200 Key exclusion criteria: polycystic kidney disease; receipt of kidney transplant Interventions N=3304 empagliflozin (at a dose of 10 mg/day) N=3305 placebo (matching placebo) Primary outcome Progression of kidney disease or death from cardiovascular causes 16.9 % 16.9 13.1 12.7 % 8 4 % https://web.pathway.md/studies/recbxMQR99r9ZzJud 1/2 6/28/23, 9:54 PM 8.4 % EMPA-KIDNEY Pathway Significant decrease 4.2 % NNT = 26 0.0 % Empagliflozin Placebo Significant decrease in progression of kidney disease or death from cardiovascular causes (13.1% vs. 16.9%; HR 0.72, 95% CI 0.64 to 0.82) Secondary outcomes No significant difference in hospitalization for HF or death from cardiovascular causes (4% vs. 4.6%; HR 0.84, 95% CI 0.67 to 1.07) Significant decrease in the incidence of hospitalization for any cause (24.8 events /100 py vs. 29.2 events /100 py; HR 0.86, 95% CI 0.78 to 0.95) No significant difference in death from any cause (4.5% vs. 5.1%; HR 0.87, 95% CI 0.7 to 1.08) Safety outcomes No significant difference in serious adverse events. Conclusion In patients with CKD with an eGFR 20 and < 45 mL/min/1.73 m , or 45 and < 90 mL/min/1.73 m with a urinary albumin-to-creatinine ratio 200, empagliflozin was superior to placebo with respect to progression of kidney disease or death from cardiovascular causes. Reference EMPA-KIDNEY Collaborative Group, William G Herrington, Natalie Staplin et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117-127. Open reference URL https://web.pathway.md/studies/recbxMQR99r9ZzJud 2/2